Inclusion of targeted skin products in the pre-surgical treatment regimen of peripheral lymphedema & lipedema.

Advanced lymphedema is associated with a number of adverse skin changes including color, thickening of the epidermis, dryness, and hyperkeratosis. These changes are related to prolonged lymph stasis and contribute to an increased risk of infection. Similarly, lipedema is associated with skin thickening and appearance of nodular adipose deposition. Skin care is essential in both conditions. We examined whether inclusion of targeted skin products for 2 weeks to an established pre-surgical conservative treatment program was associated with beneficial effects on the skin condition in 150 patients with lymphedema and lipedema. Patients were randomly assigned to control or one of two treatment groups. All three groups (and for both lymphedema and lipedema) demonstrated a significant reduction in softness. Dimpling/ redness was significantly reduced in the targeted skin product groups for both patients with lymphedema or lipedema. Only patients with lipedema demonstrated a significant reduction in dryness/ hyperkeratosis following targeted skin product treatment. This study demonstrates that short-term use of targeted skin products in both patients with lymphedema and lipedema can be of benefit and further studies are needed to replicate these results and explore possible mechanisms.

[1]  P. Matts,et al.  A Randomised Controlled Trial to evaluate the effect of a new skin care regimen on skin barrier function in those with podoconiosis in Ethiopia. , 2019 .

[2]  F. Boccardo,et al.  A Single-Site Technique of Multiple Lymphatic–Venous Anastomoses for the Treatment of Peripheral Lymphedema: Long-Term Clinical Outcome , 2015, Journal of Reconstructive Microsurgery.

[3]  J. M. D. de Godoy,et al.  Lipedema: Is Aesthetic Cellulite an Aggravating Factor for Limb Perimeter? , 2013, Journal of cutaneous and aesthetic surgery.

[4]  L. Kemény,et al.  Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome – systematic review , 2012, Clinical obesity.

[5]  G. Gethin,et al.  Prevalence of lymphoedema and quality of life among patients attending a hospital‐based wound management and vascular clinic , 2012, International wound journal.

[6]  C. Moffatt,et al.  The challenges of managing complex lymphoedema/chronic oedema in the UK and Canada , 2012, International wound journal.

[7]  R. Neville,et al.  Current Dilemmas and Controversy , 2011 .

[8]  M. Titheradge,et al.  The role of transforming growth factor‐β1 and oxidative stress in podoconiosis pathogenesis , 2010, The British journal of dermatology.

[9]  F. Boccardo,et al.  Microsurgery for lymphedema: Clinical research and long‐term results , 2010, Microsurgery.

[10]  K. Alitalo,et al.  Dermal collagen and lipid deposition correlate with tissue swelling and hydraulic conductivity in murine primary lymphedema. , 2010, The American journal of pathology.

[11]  G. Woodruff,et al.  Lymphatic lipid transport : sewer or subway ? , 2010 .

[12]  P. Scherer,et al.  Mechanisms of obesity and related pathologies: The macro‐ and microcirculation of adipose tissue , 2009, The FEBS journal.

[13]  G. Davey,et al.  Development and testing of a de novo clinical staging system for podoconiosis (endemic non‐filarial elephantiasis) , 2008, Tropical medicine & international health : TM & IH.

[14]  P. Carmeliet,et al.  Lymph makes you fat , 2005, Nature Genetics.

[15]  N. Liu Trafficking of hyaluronan in the interstitium and its possible implications. , 2004, Lymphology.

[16]  H. R. Maurer,et al.  Bromelain: biochemistry, pharmacology and medical use , 2001, Cellular and Molecular Life Sciences CMLS.

[17]  J. Casley‐Smith Benzo-pyrones in the treatment of lymphoedema. , 1999, International angiology : a journal of the International Union of Angiology.

[18]  P. Novotny,et al.  Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. , 1999, The New England journal of medicine.

[19]  L. Zhang,et al.  Changes of tissue fluid hyaluronan (hyaluronic acid) in peripheral lymphedema. , 1998, Lymphology.

[20]  A. Szuba,et al.  Lymphedema: Anatomy, Physiology and Pathogenesis , 1997, Vascular medicine.

[21]  R. G. Morgan,et al.  Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. , 1993, The New England journal of medicine.